Xeltis' Series C Round

Xeltis raised a round of funding on November 15, 2017.

Xeltis is developing synthetic biodegradable heart valves and blood vessels ("matrices"), enabling a completely new therapeutic category called Endogenous Tissue Growth ("ETG"). Xeltis' proprietary te…

Articles about Xeltis' Series C Round: